This phase II study evaluates whether early treatment with mycophenolate mofetil (MMF) plus prednisone improves liver inflammation caused by immune checkpoint …

Immune-mediated HepatitisImmune-related Adverse Event

~Estimated

~$10 – $6,250

Fox Chase Cancer CenterNCT07663422

A Phase 1 Pharmacokinetic Study of Therapeutic Plasma Exchange for Severe Immune-Related Adverse Events From Immune Checkpoint Inhibitors

The purpose of this study is to characterize the pharmacokinetics of one or more ICIs during and after TPE/PLEX in patients with severe irAEs.

Immune-related Adverse Event

~Estimated

~$10 – $750

University of ChicagoNCT07756242